Rituximab is a medication used in this trial as part of the standard treatment for pemphigus. It works by targeting specific cells in the immune system that are involved in the disease process, helping to reduce inflammation and prevent further damage to the skin and mucous membranes.

Corticosteroids are also part of the standard treatment in this trial. They are used to reduce inflammation and suppress the immune system, which can help control the symptoms of pemphigus and prevent flare-ups.

The trial also involves a personalized maintenance therapy approach. This strategy uses the levels of specific antibodies in the blood, known as anti-desmoglein antibodies, to determine the risk of disease relapse. Patients identified as having a high risk of relapse may receive additional infusions of rituximab to help maintain disease control.

Pemphigus Vulgaris – Pemphigus Vulgaris is an autoimmune disease characterized by the formation of blisters and erosions on the skin and mucous membranes. It occurs when the immune system mistakenly attacks proteins in the skin, leading to the separation of skin cells. This results in painful, fluid-filled blisters that can rupture easily. The disease often begins in the mouth and can spread to other areas of the body. Over time, the blisters may become widespread, causing significant discomfort and potential complications if not managed properly.

Pemphigus Foliaceus – Pemphigus Foliaceus is a less severe form of pemphigus that primarily affects the skin, causing superficial blisters and crusty sores. Unlike Pemphigus Vulgaris, it does not typically involve the mucous membranes. The blisters in Pemphigus Foliaceus are more superficial and tend to rupture easily, leading to crusting and scaling. The disease often starts on the face and scalp and can spread to other parts of the body. It progresses with periods of flare-ups and remissions, and the severity can vary among individuals.